Benitec Biopharma Inc.BNTCNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank50
3Y CAGR-34.0%
5Y CAGR-14.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-34.0%/yr
Annual compound
5Y CAGR
-14.4%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 17.45% |
| 2024 | 22.19% |
| 2023 | 13.33% |
| 2022 | 60.57% |
| 2021 | 133.92% |
| 2020 | 38.05% |
| 2019 | -57.05% |
| 2018 | -4.89% |
| 2017 | -46.37% |
| 2016 | 107.72% |